Table 3. Polymorphisms in the C-terminal region of pbp5 a.
Allele | Sourceb | ST | 426 | 461 | 462 | 466 | 466′ | 470 | 476 | 477 | 485 | 496 | 497 | 499 | 525 | 546 | 558 | 582 | 586 | 629 | MIC range |
Reference X84860 | M | Q | V | S | x | H | A | L | M | N | F | A | E | N | A | G | V | E | |||
1 | D (5x) | 19 (2x), 454, 455, 457 | I | - | - | - | - | Q | - | - | - | K | - | T | D | - | - | - | - | V | 128–256 |
2 | D (2x) | 168 (2x) | - | - | - | - | - | Q | - | - | T | K | - | T | D | - | - | - | L | V | 128–256 |
3 | D (4x), C(1x) | 274 (4x), 458 | - | K | - | - | S | Q | - | - | A | K | - | T | D | - | - | - | L | V | ≥512 |
4 | D (3x), H (1x) | 16, 148, 373, 393 | - | K | - | - | S | Q | - | - | A | K | - | T | D | - | - | - | - | V | ≥512 |
5 | D (1x), H(1x) | 456 (2x) | - | - | - | D | S | Q | - | - | A | K | - | T | D | - | - | - | L | V | >512 |
6 | C (2x) | 477, 266 | - | - | - | D | S | Q | S | M | - | K | L | T | D | - | - | - | L | V | >512 |
7 | C (1x) | 264 | - | - | - | D | S | Q | S | - | - | K | L | T | D | - | - | - | - | V | 256 |
8 | C (6x), D (9x), H (1x) | 18, 192 (2x), 266 (11x), 453, 459 | - | - | - | - | S | Q | - | - | A | K | - | T | D | - | - | - | - | V | ≥512 |
9 | D (1x) | 128 | - | - | - | - | S | Q | - | - | T | K | - | T | D | - | - | - | - | V | 64 |
10 | C (1x) | 78 | - | - | A | - | S | Q | - | - | A | K | - | T | D | T | T | S | - | V | >512 |
Amino acid mutations that contribute to ampicillin resistance are indicated in bold [15]. The one-letter abbreviation code is used to denote the amino acids. The – sign indicates no change in amino acid compared to the reference allele.
Source (and frequency) of the isolates carrying a particular allele: D = dog; C = cat; H = human.